Introduction
RNAi (RNA interference) therapeutics is a powerful gene therapy technique for suppressing specific genes in the cells and hence has a great potential in biomedical applications including in the treatment of genetic disorders, cancer, viral infections and autoimmune diseases [1] [2] [3] [4] . In 1998, Andrew Fire and coworkers reported the gene silencing in the nematode Caenorhabditis elegans by double stranded RNA [5] . The first successful small interfering RNA (siRNA) treatment of gene silencing was achieved in hepatitis C virus. Since then gene therapy opened a new horizon for treating genetic disorders with RNAi [6] . Even though use of siRNA is effective, efficient and safe, in vivo delivery of siRNA to target tissues remains a key challenge for clinical implementation. As siRNA is negatively charged molecule, it is difficult to penetrate into the cell membrane [7] . Virus mediated nucleic acid delivery was adopted as an option [8] .
Usually in viral delivery, very small pieces of DNA are introduced into the 57) of sequence (Arg -Lys -Lys -Arg -Arg -Gln -ArgArg -Arg) was purchased from Sigma Aldrich. PNA-NLS (H-TCAACGTTAGCTTCACC-PKKKRKV-NH 2 ) was purchased from PNA Bio, Inc. USA. Polyvinyl alcohol (PVA) and ethyl acetate were purchased from Kanto Chemicals, Japan. Acid yellow Tartrazine was purchased from Tokyo Chemical Industry, Japan. The linear DNA templates for siRNA synthesis, primers for β2-microglobulin, c-myc and n-myc were purchased from Eurofins, Germany. Neuroblastoma IMR-32 (CCL-127), colorectal carcinoma T84 (CCL-248) and normal cortical neuron HCN-2 (CRL-10742) were purchased from American Type Culture Collection, USA. Ambion siRNA construction kit, Life technology, Japan was used for the synthesis of siRNA and quantified using Ribogreen reagent (Qubit™ RNA Assay Kits, Invitrogen, Japan). For cell proliferation study, MTS-based colorimetric assay (Cell titer 96 AQ One Cell Proliferation assay, Promega Corporation's, USA) was used. Alexa Fluor® 488 annexin V/ Dead Cell Apoptosis Kit (Invitrogen) was used for studying apoptosis. RNeasy Mini kit (Qiagen) was used for isolation of mRNA. One Step SYBR PrimeScript PLUS RT-PCR Kit (Takara Bio Inc) was used for qRT-PCR.
Synthesis of PLGA Hollow nanoparticle preparation (PLGAHNPs)
Hollow nanoshells were synthesized as described in our previous paper [29] , using simple solvent emulsion evaporation method. Briefly 50 mg of PLGA was dissolved in 1ml of ethyl acetate. This solution was vortexed for one hour. The above vortexed PLGA solution was emulsified in 5% (w/v) of 2 ml of PVA solution. This solution was stabilized in 0.05% (w/v) PVA solution to form colloidal solution containing PLGAHNPs.
siRNA duplex preparation
The silencer siRNA used in the experiment, corresponding to sequence 447 -449 relative to the start codon of c-myc Gene bank Accession no. AA149343 and sequence 997 -998 of n-myc mRNA sequences Gene Bank Accession no. X03294 were synthesized after in vitro transcription and hybridization of the sense and antisense strands. siRNA synthesis was carried out according to the manufacturer's instruction. Briefly, the siRNA duplexes were synthesized by in vitro transcription with T7 RNA polymerase on linear DNA templates selecting part of mRNA reference sequences from human n-myc and c-myc. The DNA strands designed and used for synthesizing siRNA were: c-myc sense DNA 5`-AATAATTGGCCCAAGTCATTG-CC-TGTCTC-3` antisense DNA 5`-AACAATGACTTGGGCCAAT-TA-CCTGTCTC-3`
n-myc sense DNA 5`-AAGTCAAACTCGAGGTCTGGG-CCT-GTCTC-3` antisense DNA 5`-AACCCAGACCTCGAGTTT-GAC-CCTGTCTC-3`
The above 29-mer DNA oligonucleotides (template oligonucleotides) with 21 nucleotides (nt) encoding siRNA and 8 nt complementary to the T7 Promoter Primer cells. However, these methods are labor-intensive and expensive. Apart from this, risk of random insertion in the genome, cytophathic effects and mutagenesis are few other issues associated with viral gene delivery [9] . Therefore, viral delivery faded gradually from bioresearch field [10] . Recently, non-viral siRNA delivery systems using nanoparticles (NPs) including cationic lipids, liposomes, cationic polymers, peptide-conjugates, gold NPs, quantum dots and modified siRNA [11] [12] [13] [14] [15] [16] [17] [18] are preferred. NPs made of polymers like polyethylenimine form conjugates with siRNA through electrostatic interactions. However, these cationic NPs have toxicity issues [19] [20] [21] . Meanwhile inorganic NPs like gold NPs and quantum dots showed great potential in siRNA delivery, researchers are still optimizing and studying the surface chemistries and investigating their long-term toxicity issues [22, 23] .
Further, for the efficient use of NPs in siRNA delivery, researchers still need to overcome certain problems related to cellular uptake, degradation and renal clearance [24] . While siRNA along with the NPs were administered intravenously, they were subjected to degradation by endogenous enzymes in the blood stream. Therefore NPs should be designed in such a way that they are effective and non-toxic. Also post-injection, NP-siRNA conjugates must navigate through the circulatory system, avoiding kidney filtration, uptake by phagocytosis, aggregation with serum proteins and escape enzymatic degradation [25] . Hence, there is a need to formulate siRNAencapsulated NPs that can target the nucleus of cancerous tissue [25] [26] [27] .
Until now, biocompatible and biodegradable, PLGA NPs was used for siRNA delivery. These polymeric NPs showed enhanced encapsulation efficiency but had very low release efficiency [28] . This is because the siRNA gets entrapped in the PLGA solution during encapsulation process and its degradation takes longer time, even though PLGA is biodegradable [28] . To solve this problem we have developed PLGA hollow NPs (PLGAHNPs) that could encapsulate and efficiently release siRNA. In our previous work we showed the potential ability of PLGANPs and PLGAHNPs in drug encapsulation and release efficiency [29] .
In this study, we developed a therapeutic approach using layer-by-layer (LBL) NPs to treat aggressive cancer. The advantages of LBL technique include ease of preparation, versatility, and capability of incorporating controlled high loadings of different types of biomolecules in layers. By taking advantage of this technique, we incorporated layers of Tat peptide and peptide nucleic acid-nucleolus localizing signal (PNA-NLS) on PLGAHNPs of homogenous size below 100 nm (68-70 nm). These targeting moieties layered on siRNA encapsulated PLGAHNPs enhanced the uptake of our siRNA delivery targeted cells.
Materials and Methods:
Materials PLGA; (50:50, Mw 17000 ~ 70000), Rhodamine 6G, Fluorescein isothiocyanate isomer-I (FITC) were purchased from Sigma Aldrich, USA. Tat peptide (TAT, 49-were synthesized. In separate reactions, the two template oligonucleotides were hybridized to a T7 Promoter Primer that is provided in the kit that contains a T7 promoter sequence. The 3' ends of the hybridized DNA oligonucleotides were extended by the Klenow fragment of DNA polymerase to create double-stranded siRNA transcription templates. The sense and antisense siRNA templates were transcribed by T7 RNA polymerase and the resulting RNA transcripts were hybridized to create dsRNA. The dsRNA consisted of 5' terminal single-stranded leader sequences, a 19 nt target specific dsRNA, and 3' terminal UUs. The leader sequences are removed by digesting the dsRNA with a single strand specific ribonuclease supplied in the kit. Overhanging UU dinucleotide remained on the siRNA and this helped in further transfection. The DNA template is removed at the same time by a deoxyribonuclease. The resulting siRNA is purified by elution method, which removes excess nucleotides, short oligomers, proteins and salts in the reaction mixture. The end product is a double-stranded 21-mer siRNA with 3' terminal uridine dimers that can effectively reduce the expression of target mRNA when transfected into mammalian cells.
Our siRNA sequences were designed according to the guidelines by Ui-Tei et al. [30] and homology to other genes were confirmed using BLAST. The molarity and concentration of siRNA prepared were calculated according to the instructions in user manual for siRNA synthesis.
Preparation of siRNA encapsulated PLGA NPs
siRNA encapsulated PLGA NPs were synthesized using the simple solvent emulsion evaporation method. In brief, different concentration of siRNA ranging from 100, 500, 1000, 1500, 2000 and 2500 µg/ml solubilized in Tris-EDTA buffer (10 mM Tris, 1 mM EDTA, pH 7.5, TE buffer) were mixed with 3 mg of PLGA and 60 µl of ethyl acetate in a closed vial and was emulsified to synthesize siRNA encapsulated PLGAHNPs. The NPs were collected by centrifugation at 10000 rpm for 8 min and these NPs were further washed with 5 ml of diethylpyrocarbonate (DEPC)-treated water, vacuum dried and stored at -80 ºC till further use.
siRNA encapsulation was done according to the protocol reported by Cun et al. [31] 2 mg each of NPs containing different concentrations of siRNA was dissolved in 200 µl of chloroform and 500 µl of TE buffer. This mixture was rotated for one hour, and the phases were separated by centrifugation for 30 min at 12000 rpm at 4 o C. The supernatant was kept at room temperature for 5 min for complete evaporation of chloroform. The samples were diluted in TE buffer and concentration of siRNA was measured by Ribogreen reagent. Readings were taken using plate reader at excitation wavelength of 485 nm and emission wavelength of 520 nm. Each sample was assayed in triplicates and the following equations were used to calculate the amount of siRNA encapsulated. The amount of siRNA used for encapsulation
Release of siRNA
The release of siRNA was determined from PLGAHNPS using UV-Vis spectrophotometer. 10 mg of siRNA encapsulated PLGAHNPs was suspended in 10 ml each of Tris-HCl buffer of pH 7.4 and 4.2. Further they were filtered through 0.45, 0.25 and 0.15 µm pore sized Whatman filters to obtain NPs ranging from 50 -400 nm. Further, aliquots of 1 ml of the above solutions were prepared and placed on a rotator with a stirring speed of 100 rpm at 37 o C for 72 h. At specific time intervals (0, 2, 4, 6, 12, 24, 36, 48, 60 and 72 h) samples were centrifuged at 14000 rpm for 8 min at 4 º C. Then, the supernatant was used to estimate the amount of siRNA released from HNPs by qualitatively analyzing the concentration of siRNA at 260 nm [32, 33] . Each sample was assayed in triplicates and the release efficiency was determined.
Preparation of functionalized PLGA HNPs
The synthesized siRNA encapsulated PLGAHNPs were functionalized with TAT and PNA-NLS for studying anticancer activity in two different cancer cell lines-IMR-32 and T84, and normal cell line HCN-2. 1 mg of siRNA encapsulated PLGAHNPs was functionalized with PNA-NLS and TAT peptide. Two types of functionalized NPs were prepared, a) siRNA encapsulated PLGAHNPs-coated-PNA-NLS (PAPLGAHNPs), b) TAT peptide coated over siRNA-PNA-NLS-siRNA encapsulated PLGAHNPs (TPAPLGAHNPs) The reason behind coating TAT on PAPLGAHNPs was to increase cell permeability.
PNA-coated NPs were developed by incubating 1 mg of PLGAHNPS in 1, 2.5, 5, 10, and 20 µmol/L of PNA-NLS dissolved in 10 mM Tris buffer (pH 8) for 4 h at room temperature. After incubation, PLGA-PNA NPs were collected by centrifugation at 8000 rpm for 30 min at 4 º C. They were resuspended again in fresh PNA solution and incubated on ice for an additional 3 h without rotation. These PNA-PLGA NPs were collected by centrifugation at 8000 rpm for 20 min at 4 º C and were resuspended in fresh deionized water. These synthesized PAPLGAHNPs were rotated for 20 min prior to experiment. For the preparation of PLGA-PNA-siRNA conjugates, the above prepared NPs were suspended in anti-n-myc and anti-c-myc siRNA of different concentrations (70 nM and 80 nM) with 10 mM of NaCl and 1 mM Tris buffer of pH 7.4 for 20 min at room temperature. After incubation the particles were collected by centrifugation at 5000 rpm for 10 min at 4 º C. Further, for preparation of
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TAT-siRNA-PNA-PLGAHNPs conjugates, the above prepared siRNA-PNA-PLGANPs were incubated in 1mM PBS containing TAT with concentration of 10, 50, 100 and 150 µg/ml at room temperature and kept for rotation. The functionalized NPs were collected by centrifugation at 8000 rpm for 10 min [34] [35] [36] .
Preparation of fluorescently labeled NPs
Two types of fluorescently labeled NPs were prepared for studying the cellular and nuclear uptake. As we wanted to determine the site specificity and accumulation of NPs, we used PNA-NLS and TAT to target the cells. The first type of fluorescent PNA-PLGAHNPS (PAPHNPs) were prepared by conjugating Rhodamine -PNA complex on Tartrazine TAT peptide and FITC-DMSO solutions for 20 min. These NPs were washed in deionized water to remove excess FITC and the NPs were collected and resuspended in deionized water for further studies.
Technically, four types of siRNA encapsulated PLGAHNPs namely a) PAPLGAHNPs b) TPAPLGAHNPs (non-fluorescent NPs), c) PAPHNPs and d) TPAPHNPs (fluorescent NPs) moieties were synthesized as represented in figure 1 for studying the in vitro effects on cancer cells. Cell proliferation ability, mode of cell death, uptake of NPs in cancer cells and downregulation of MYC-gene were studied. These NPs were stored at -20 º C till further use.
Characterization of NPs
The NPs (1 mg/ml) were suspended in deionized water and were characterized for their shape and size using Scanning Electron Microscopy (SEM, JEOL, JSM-7400F) and Transmission Electron Microscopy (TEM, JEM 2100, JEOL). SEM was performed at 5 kV and TEM at 180 kV. Zeta potential and Dynamic Light Scattering (DLS) of PAPLGAHNPs, TPAPLGAHNPs, PAPHNPs and TPAPHNPs were analyzed using Malvern Zetasizer Nano.
Cell culture
Monolayer of IMR-32 and T84 were maintained within 1-8 passages [37, 38] . IMR-32 cells were cultured for 3 days in Eagle's Minimum Essential Medium (EMEM), with 10% of heat inactivated fetal bovine serum (FBS) and antibiotics. The T84 cells was cultured for 5 days to get a monolayer in Dulbecco's Modified Eagle's Medium (DMEM) -Ham F12K media with 5% serum and antibiotics. The HCN-2 cells were cultured and maintained in DMEM, with 10% FBS and antibiotics. For studying the cell proliferation, flow cytometry and relative mRNA expression level, these cells were grown to confluency with a viability of 85 -99%. The viability of the cells was checked using trypan blue assay.
Analysis of cell proliferation
IMR-32, T84 and HCN-2 cells were seeded in 96-well culture plates (5x10 4 cells/well) and treated with different concentration of NPs containing various concentrations of siRNA and were incubated overnight. MTS-based colorimetric assay was used for cell proliferation study, where PAPLGAHNPs and TPAPLGAHNPs containing different concentrations of anti-c-myc and anti-n-myc siRNA (50, 70, 80 nM) were used. The absorbance was measured at 490 nm [39] .
Flow cytometry
The mode of cell death and effect of the functionalized NP on the cells were confirmed by flow cytometry. The cells were seeded at a concentration of 5 x 10 3 cells/well in 6-well plates and treated with functionalized NPs. IMR-32 cells were incubated overnight with 200 µg/ml each of TPAPLGAHNPs and PAPLGAHNPs keeping 70 nM of anti-n-myc siRNA in PLGAHNPS. While 150 µg/ml of TPAPLGAHNPs and 250 µg/ml of PAPLGAHNPs with concentration of 80 nM of anti-c-myc siRNA were treated with T84 cells. The HCN-2 cells were incubated with 200 µg/ml (70 nM of anti-n-myc siRNA) and 150 µg/ml (80 nM of anti-c-myc siRNA) of TPAPLGAHNPs; 200 µg/ml (70 nM of anti-n-myc siRNA) and 250 µg/ml (80 nM of anti-c-myc) of PAPLGAHNPs.
The cell death was observed in both the cancer cells using live and dead cell assay kit. Flow cytometry measurements were taken at fluorescence emissions of 530 nm and 575 nm [40] . Same procedure was carried on normal cells to determine the effect of NPs.
Cellular uptake of NPs
To 
Uptake in nucleus
Nuclear uptake of the NPs was confirmed by confocal microscopy. Cells were incubated with functionalized fluorescent NPs (TAT-anti MYC siRNA-PNA-NLSPLGAHNPs) for 4 h. The 3D reconstruction of in vitro cultures was carried out to investigate the accumulation and nucleus targeting specificity of NPs that were present in and around nucleus [42] .
Morphologic analysis
HCN-2, IMR-32 and T84 cells were cultured for 3 days in six well plate containing PAPLGAHNPs and TPAPLGAHNPs. Phase contrast microscopy was used to check the morphological changes in cells after co-incubation with the NPs.
RNAi treatment
Investigation of gene inhibition was studied on HCN-2, IMR-32 and T-84 cells. The cells were grown to confluency and
Gcell Scell treated with 250 µg/ml (70 nM of anti-n-myc siRNA) and 150 µg/ml (80 nM of anti-c-myc siRNA) of TPAPLGAHNPs; 250 µg/ml (70 nM of anti-n-myc siRNA) and 350 µg/ml (80 nM of anti-c-myc siRNA) of PAPLGAHNPs. Cells were treated and incubated overnight for two days with NPs. The cells were then harvested to check n-myc and c-myc mRNA expression by qRT-PCR [43] .
Relative gene expression studies using qRT-PCR Cells were harvested and washed with DPBS. Total RNA was isolated from these cells using RNeasy Mini kit and quantified by UV spectrophotometry [43] . Complementary DNA (cDNA) was prepared from 1.56 µg of total cellular RNA using oligo-dT18 primers according to the manufacturer's protocol. Relative gene expression of c-myc, n-myc mRNA were compared with that of human β2-microglobulin mRNA was determined by qRT-PCR. e concentration of mRNA used was 10 µM, with 1 µl primer mix (sense and antisense) in 25 µL q-PCR reaction mixture. The q-PCR was performed using One Step SYBR PrimeScript PLUS RT-PCR Kit based on the manufacturer's protocol after optimization. Inhibition of c-myc and n-myc mRNA was determined by comparison of the ratio between c-myc and n-myc, and β2-microglobulin mRNA for the treated groups against the untreated group. RT-PCR products were subjected to electrophoresis on 2% agarose gel and visualized by ethidium bromide staining. Agarose gel was photographed and intensities were determined using BioRad GS710. The standard curve obtained from PCR showed the level of mRNA concentration present in the treated and nontreated cells. We have calculated the relative mRNA expression by using the equation 4.
E= (10 -1/slope -1) x 100 ...(4)
Results
Nanoparticle characterization SEM, TEM and DLS were used to characterize the NPs. Figure 2A represents the SEM image of PLGAHNPs that were spherical in shape and hollow. In TEM image ( Figure 2B) , we observed the absence of inner core in the NPs. Compared to figure 2B, in figure 2C we could observe the presence of light shadow region, depicting the presence of siRNA encapsulated in the hollow NPs. According to the DLS ( Figure 2D ) the mean diameter of siRNA encapsulated PLGAHNPs was around 70 nm after it was filtered through 0.15 µm Whatman filter.
siRNA encapsulation efficiency
The encapsulation efficiency of siRNA into NPs plays a significant role in "non-viral gene delivery". It is reported that the encapsulation efficiency of non-hollow PLGANPs is affected by the concentration of PLGA used to synthesize the NPs [31, 44] . We have used PLGAHNPs to encapsulate higher amount of siRNA and protect it from degradation. From figure 3 the amount of siRNA encapsulated was 1997 ± 0.76 µg/ml when 2000 µg/ml of siRNA was used for encapsulation. The efficiency of siRNA encapsulation was 99 ± 0.42% as calculated using equation 2. siRNA release efficiency PLGA NPs favor siRNA delivery systems because they can readily be surface-modified to enhance targeting or cellular uptake [45] . We found that PLGAHNPs show efficient encapsulation and in vitro release of siRNA and have the capacity to protect the siRNA from the external environment. In our experiment the PLGA HNPS were filtered through 0.45, 0.25 and 0.15 µm sized Whatman filters. As shown in figure 4A we obtained NPs of mean size around 260 ± 0.49, 105 and 70 ± 0.77 nm respectively after filtering. Further from graph in figure 4B and C we concluded that the maximum siRNA release is from 70 nm sized PLGAHNPS when compared to other larger PLGAHNPS. Maximum amount of siRNA release in pH 7.4 was 1786 µg/ml, and the release efficiency was 89 ± 0.89%. The siRNA release from other NPs was comparatively lower (78% for 105 nm and 0.00015% for 260 ± 0.49 nm). From figure 4C we observed that the NPs of 70 nm showed 94% of siRNA release after 12 h in pH 4.2 and sustained release after 12 h. We performed siRNA release in pH 4.2 to mimic the acidic environment of endosomes in the cells [29, 31] .
At pH 4.2 the release efficiency of 105 nm was 84% and of 260 ± 0.49 nm was 4x10 -4 %. For further studies with targeting moieties, NPs of size 70 nm were selected. The size, siRNA encapsulation and release efficiency was suitable for siRNA delivery in cancer cells. It is reported that the NPs of size ranging from 70-200 nm are best suited for in vitro and in vivo delivery [46] .
Characterization of functionalized NPs
TAT and PNA-NLS were attached to the surface of siRNA (anti-c-myc and anti-n-myc) encapsulated PLGAHNPS by layer-by-layer assembly. After the incubation and addition of targeting moieties, hydrodynamic size and zeta potential were analyzed. We observed that the targeting moieties formed a layer on the HNPs. Figure 5 showed the SEM image of these functionalized NPs. Table 1 summarizes surface charge, size and encapsulation efficiency of PLGAHNPS, PAPLGAHNPs, TPAPLGAHNPs, PAPHNPs and TPAPHNPs. The size of PLGAHNPS increased from 58 nm to 123 ± 0.87 nm after functionalizing with targeting moieties to form TPAPLGAHNPs. The functionalized fluroscent NPs were larger in size than non-fluroscent NPs. The surface charge of PLGA NPs without fluorescent moiety was -7 mV. After conjugation of PNA and TAT peptide, the surface charge was +12 and +29 mV respectively, suggesting the formation of peptide layer on PLGAHNPS. A layer of anti-c-myc and anti-n-myc siRNA was inserted in between two peptides. This contributed an increase in hydrodynamic size and decrease in surface charge to -5 mV after the formation of PNA layer. Although the TAT layer increased the size, the surface charge was maintained to +29 mV creating cationic TPAPLGAHNPs, which made the penetration into the cell membrane easy [35, 47] . The targeting moieties converted the PLGAHNPs to cationic polymeric NPs, which made them ideal carriers for gene delivery [47] . Thus after the complete functionalization of PLGAHNPS, the cellular and nuclear uptake were studied in different cell lines.
Effect of NPs on cell
The minimum inhibitory concentration (MIC) required for inhibiting cell proliferation was determined using MTS assay. Cancer cells were treated with different molar concentrations of anti-MYC-siRNA (anti-n-myc siRNA for IMR-32 cells and anti-c-myc siRNA for T84) ranging from 50 -90 nM. From figure 6B, D and F we can observe the effect of optimized molar concentration of anti-MYC-siRNA on IMR-32, T84 and HCN-2. 70 nM of anti-n-myc siRNA was optimized as MIC required for inhibiting IMR-32 cells and 80 nM of anti-c-myc siRNA was required to inhibit T84 cells. There was no significant effect on proliferation observed in HCN-2 cells. Further we treated IMR-32, T84 and HCN- Abréviations: PAPLGAHNPs-PNA layered on PLGA-siRNA encapsulated hollow nanoparticles, TPAPLGAHNPs-TAT, siRNA, PNA layered on PLGA-siRNA encapsulated hollow nanoparticles. Further we performed flow cytometry experiment to determine the effect of functionalized NPs on IMR-32, T84 and HCN-2 cells (Figure 7) . The viability of untreated IMR-32, T84 and HCN-2 cells was 96%, 89% and 98% respectively. We observed 67.31% and 49.12% of cellular death in IMR-32 and T84 cells after treatment of TPAPLGAHNPs encapsulated with anti-MYC-siRNA after 4 h of incubation. Also, 9.42% and 12.16% of cellular death in IMR-32 and T84 cells after treatment of PAPLGAHNPs encpasulated with anti-MYC-siRNA after 4 h of incubation. Treatment of functionalized NPs did not have significant effect on HCN-2 cells ( Figure 7B) . Also, 78.24% and 78.12% of cellular death was observed in IMR-32 and T84 cells after overnight incubation with TPAPLGAHNPs while 46% and 51.67% of cellular death was observed in IMR-32 and T84 cells after overnight incubation with PAPLGAHNPs encapsulated with anti-MYC-siRNA ( Figure 7A ). There was no effect on HCN-2 cells after overnight incubation with functionalized NPs. The results are tabulated in Table 2 Cellular and nuclear uptake of PAPHNPs and TPAPHNPs
The cellular uptake of two different types of NPs (PAPHNPs and TPAPHNPs) were observed after 4 h of incubation and overnight incubation of NPs with cancer cells and normal cells. The 4 h as well as overnight incubation of NPs showed the presence of fluorescence in cytoplasm and nucleus as observed in figure 8 . It is known that the successful endosomal escape is crucial for the siRNA carriers to improve siRNA silencing efficiency [24] . We have observed co-localization of PNA-Rhodamine and Tartrazine-PLGAHNPS in cytoplasm and nucleus of cancer cells by confocal microscopy. Within 2 cells with functionalized NPs encapsulated with optimized molar concentration of anti-MYC-siRNA ranging from 50 to 250 µg/ml. From figure 6A, C and E we observe the MIC Abbreviations: PAPHNPs-PNA-Rhodamine layered on tartrazine PLGAsiRNA encapsulated hollow nanoparticles, TPAPHNPs-TAT-FITC, siRNA, PNA-Rhodamine layered on tetrazine-PLGA-siRNA encapsulated hollow nanoparticles 4 h of coincubation with PAPHNPs and TPAPHNPs, the NPs were randomly distributed all over the cytoplasm. In figure 8A we have observed co-localization indicating the presence of PNA-Rhodamine, FITC-TAT and Tartrazine-PLGAHNPS in IMR-32 and T84 cells. The single cell uptake as observed in figure 8B of IMR-32 and T84 represents that NPs were present both in cytoplasm and in nucleus. In figure  8C we observed morphological changes in cancer cells after overnight incubation with fluorescent NPs. In figure 8D , cells treated with Tartrazine-PLGAHNPs did not show any cellular or nuclear uptake. According to figure 8E and F cytosol and nuclear uptake of NPs was less in HCN-2 cells. These results suggest the enhanced uptake of NPs in cancer cells.
We have observed that the cells treated with TPAPHNPs showed the uptake of NPs into the nucleus. Moreover, the cells treated with PAPHNPs showed less uptake in nucleus compared to TPAPHNPs. This may be because TAT protects the NPs from external environment. Based on figure 8 quantification of fluorescence intensity was calculated using equation 3 and presented in figure 9 . The fluorescence intensity of Rhodamine was less in cells treated with PAPHNPs. In IMR-32 and T84, the presence of FITC in cytosol was high, while less in nucleus. This concluded that TAT helps the PAPHNPs to cross-cellular membrane and release siRNA.
The confocal images in figure 8C and the phase contrast microscopy images in figure 10 revealed that the cellular uptake of TPAPHNPs show morphological changes after the overnight incubation. The TPAPHNPs treated IMR-32 underwent shrinkage and were clumped. We also observed that the IMR-32 cells lost adherence and started floating. We have observed same effect in T84 cells. We observed no adverse effect of NPs on HCN-2 cells. These results clearly prove that the NPs resulted in cancer cell death. Further to confirm nuclear uptake of NPs, cells were treated with TPAPHNPs and were visualized by 3D imaging after 4 h (Figure 11 ). In figure 11A and B we observed the nuclear uptake and colocalization of PNA-Rhodamine, TAT-FITC and Tartrazine-PLGAHNPS. The nucleus was stained with Hoechst stain. We have observed higher nuclear uptake of PNA conjugated NPs in IMR-32 and T84. The presence of PNA-Rhodamine, Tartrazine-PLGAHNPS in nucleus determined the uptake of NPs through the nuclear membrane. The process of internalization initiates during the first 4 h. In figure 11C and D the orthogonal section of HCN-2 nucleus proved that NPs were completely absent inside the nucleus. From figure 11 we inferred that nuclear uptake of siRNA encapsulated PLGAHNPS were mediated by PNA and TAT. 
Effect of NPs on gene expression
To investigate the RNAi efficiency with anti-n-myc and anti-c-myc siRNA, IMR-32 and T84 cells were treated with PAPLGAHNPs and TPAPLGAHNPs and the relative gene expression was studied using qRT-PCR analysis. There was significant down regulation of c-myc and n-myc gene expression. To study the relative gene expression efficacy (Figure 12 ), cells were incubated with different concentrations of siRNA encapsulated PAPLGAHNPs and TPAPLGAHNPs. IMR-32 cells were incubated with anti-n-myc siRNA (50 nM and 70 nM) and T84 cells were incubated with anti-c-myc siRNA (50 nM and 80 nM). We have observed a decrease in mRNA expression as observed in figure 12 . These results suggested 1.2 fold decrease in n-myc expression and 0.6 fold decrease in c-myc mRNA expression. To further investigate the efficiency of gene silencing, qRT-PCR was performed and compared with β2-microglobulin, a housekeeping gene. HCN-2 cells were also treated with same concentration of functionalized NPs and no effect in gene regulation was observed. The relative gene expression was calculated based on equation 4. In IMR-32 cells mRNA expression was reduced from 96.7% to 32.4% and in T84 cells from 74% to 31% when treated with PAPHNPs. On treatment with TPAPHNPs the gene expression in IMR-32 was reduced from 96.7% to 5.64% and in T84 from 74% to 8.815%. These results suggested gene silencing using sequence specific siRNA using PLGAHNPs as delivery vehicle.
Discussion
Recently RNAi therapeutic have emerged as a promising treatment to silence disease-associated genes. Numerous siRNA-based drugs especially, nanoparticle-based treatments are currently undergoing human clinical trials. The siRNA delivery using NPs have to overcome certain limitations like a) proper encapsulation and sustained release, b) escape from RNase degradation, c) targeted delivery, d) cross the cell barrier and cytosolic release, e) bind to RNA induced silencing complex (RISC) and f ) renal clearance [48] . Keeping these points in mind we have designed our NPs to overcome these issues. Targeting moieties were attached by LBL assembly to PLGAHNPS. We have demonstrated in vitro effect of siRNA encapsulated HNPs in cancer cells.
In our study, siRNA encapsulated PLGAHNPs were functionalized with PNA-NLS, a layer of siRNA and CPP using LBL assembly. Owing to the positive charge of PNA-NLS, the attachment with TAT was difficult. There are chances that the chemical modification of PNA-NLS might result in the reduction of its original activity. CPP was used to increase the cytosolic delivery. Therefore a layer of anti-MYC siRNA was added on PAPLGAHNPS, to create a negatively charged particle. Then another layer of CPP (TAT) was added. Thus our NPs were layered by cell penetrating and nucleus penetrating moieties. The size of completely functionalized NPs was 123 ± 0.87 nm. TAT peptide helps NPs to penetrate the cell membrane. As the NPs enter the cytosol the siRNA layer encounters the cytosolic enzyme degradation or may come across the DICER enzyme and degrade mRNA. However the siRNA encapsulated inside the polymer remains safe due to presence of PNA-NLS. The PNA-NLS further helps in targeting the nucleus and delivering the siRNA. Tonelli et al. reported the penetration of NLS-myc gene complex into the nucleus and had anti-myc effect in cancer cells [49] . The inhibitory effect of MYC transcription was highly selective and specific, and had antiproliferative effects in cancer cells. Therefore siRNA encapsulated polymeric NPs was delivered safely into nucleus. Once it enter the nucleus, the PNA-NLS functionalized NP is susceptible to degradation [50] . When polymer is degraded, siRNA is released and results in the downregulation of MYC gene. As the siRNA designed is sequence specific it targets the n-myc and c-myc mRNA in IMR-32 and T84 cells respectively. This results in the suppression of MYC and downregulates the gene expression resulting in cell death. Abbreviations: PAPLGAHNPs-PNA layered on tetrazine PLGA-siRNA encapsulated hollow nanoparticles, TPAPLGAHNPs-TAT, siRNA, PNAlayered on PLGA-siRNA encapsulated hollow nanoparticles
